Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone

Efstratios Kolibianakis, Evangelos Papanikolaou, Herman Tournaye, Michel Camus, Andre Van Steirteghem, Paul Devroey

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

To evaluate the effect of different human chorionic gonadotropin (hCG) doses on the ongoing pregnancy rates in patients with polycystic ovary syndrome (PCOS). DESIGN: Prospective, randomized, controlled trial. SETTING: Tertiary university referral center. PATIENT(S): Eighty PCOS patients. INTERVENTION(S): Patients were randomized to receive 10,000 IU (n = 28), 5000 IU (n = 26), or 2500 IU (n = 26) of hCG for triggering final oocyte maturation as soon as >or=3 or more follicles of 17 mm or larger were present at ultrasound. Patients were stimulated with recombinant follicle stimulating hormone (FSH) and daily gonadotropin-releasing hormone (GnRH) antagonist, starting on day 6 of stimulation. MAIN OUTCOME MEASURE(S): Ongoing pregnancy, fertilization rates. RESULT(S): The median fertilization rates were 52.8%, 65.4%, and 55.6% after administration of 10,000 IU, 5000 IU and 2500 IU, respectively. The ongoing pregnancy rates per PCOS patient receiving hCG were 26.9% (7 of 26), 30.8% (8 of 26) and 34.8% (8 of 23), respectively. CONCLUSION(S): A decrease in the dose of hCG used to trigger final oocyte maturation does not appear to affect adversely the probability of pregnancy in PCOS patients treated by IVF using GnRH antagonists and recombinant FSH, and further testing in future larger-scale trials is recommended.
Original languageEnglish
Pages (from-to)1382-1388
Number of pages7
JournalFertility and Sterility
Volume88
Publication statusPublished - 2007

Keywords

  • GnRH antagonists

Fingerprint

Dive into the research topics of 'Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone'. Together they form a unique fingerprint.

Cite this